GlassScriptPhysician profile
Jordan Leigh Malone
NPI 1043661184
$2,943.89
in general payments reported to CMS, 2019-2025
25 companies · $55.84 in 2025
The $55.84 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $969 · 2022: $943 · 2023: $597 · 2024: $380 · 2025: $55.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,032.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,032.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $532.05 | 2021-2024 | Caplyta |
| Alkermes, INC. | $422.50 | 2021-2024 | Aristada, Lybalvi |
| Abbvie INC. | $351.78 | 2021-2024 | |
| Sunovion Pharmaceuticals INC. | $215.88 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $198.67 | 2021-2024 | Fanapt |
| Axsome Therapeutics, INC. | $191.29 | 2022-2023 | Auvelity |
| Bausch Health US, LLC | $190.90 | 2021-2022 | |
| Corium, LLC | $165.45 | 2022-2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $137.73 | 2021-2023 | Rexulti, Abilify Asimtufii |
| Lundbeck LLC | $118.10 | 2021-2023 | Rexulti |
| Janssen Pharmaceuticals, INC | $49.96 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $47.84 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $41.50 | 2022-2023 | Belsomra |
| Neurocrine Biosciences, INC. | $39.11 | 2022-2024 | Ingrezza |
| Avanir Pharmaceuticals, INC. | $34.65 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $30.54 | 2023 | Quviviq |
| Tris Pharma INC | $30.18 | 2022-2024 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $23.40 | 2024 | |
| Bioxcel Therapeutics, INC. | $19.76 | 2023 | Igalmi |
| Acadia Pharmaceuticals INC | $19.41 | 2022 | |
| Neos Therapeutics, LP | $19.33 | 2025 | Adzenys Xr-Odt |
| Jazz Pharmaceuticals INC. | $17.42 | 2022 | |
| Almatica Pharma LLC | $15.99 | 2023 | Gralise |
| Novo Nordisk INC | $15.63 | 2023 | Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $14.82 | 2025 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Malone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.